Clinical trials

Salem Health has one of the most active cancer research programs in Oregon. In fact, our Clinical Research Department offers as many oncology clinical trials as large, university-based teaching hospitals. Thanks to our long standing affiliation with the Knight Cancer Institute, many OHSU clinical trials can be accessed, or followed, by our local cancer doctors.

We conduct clinical research under the same rigid ethical and professional guidelines as larger academic medical centers and are subject to the same federal standards.

If you are interested in participating in a clinical trial, read our FAQ page, talk to your doctor or call the Salem Health Clinical Research Department at 503-814-1461.

Full list of open trials below:

Protocol: Breast - A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvent Chemotherapy.
Patients will be randomized to two study groups if cancer-positive lymph nodes are identified during surgery or at final pathology. Patients will either have axillary lymph node dissection and radiation treatment combined, or only radiation treatment.
1. Patients must be at least 18 years of age.
2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy).
3. No inflammatory breast cancer.
4. No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix.
5. No neoadjuvant endocrine therapy.
6. No neoadjuvant radiation therapy.

More eligibility criteria must be met.

Protocol: Breast - S1207

Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e 3 Breast Cancer Study - evaluating everolimus with endocrine therapy.
All patients will receive endocrine therapy. Choice of therapy will depend on menopausal status and patient/ physician preference.
Patients must have a histologically confirmed diagnosis of invasive breast
carcinoma with positive estrogen and/or progesterone receptor status, and
negative HER-2, for whom standard adjuvant endocrine therapy is planned. Patients must not have metastatic breast cancer. Patients must be high risk.


The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

This is an observational study.
Must be able to provide written informed consent form (ICF)
Newly diagnosed,* primary or secondary MDS or AML, or ICUS
Cohort assignment confirmed by Central Eligibility Review
AML patient must be at least 55 years of age at the time of ICF signature
MDS/ICUS patient must be at least 18 years of age at the time of ICF signature
Must be willing and able to complete enrollment and follow-up HRQoL instruments, for which patients must be proficient in either English or Spanish.

Protocol: Lung-MAP - S1400

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (LUNG-MAP)
After completing screening, participants have the option to be assigned to a sub-study based off the biomarker findings.
Screening/Pre-Screening Criteria:
1. Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the lung confirmed by tumor biopsy and/or fine-needle aspiration.
2. Patients must either be eligible to be screened at progression on prior treatment or to be pre-screened prior to progression on first-line treatment.
3. Patients must not have received docetaxel as treatment for Stage IV disease.
4. Patients must not have a known EGFR mutation or ALK fusion
5. Patients must be ≥ 18 years of age.

More eligibility criteria must be met.

Protocol: Lung - NILE Trial

Noninvasive vs. Invasive Lung Evaluation
Blood will be collected from study patients prior to first line treatment, then approximately 2 weeks post systemic therapy, then either at progression or 12 months, whichever occurs first.
• Patients with NSCLC
• No prior treatment for advanced-stage NSCLC:
• Age ≥ 18 years
• Ability to understand a written informed consent document, and the willingness to sign it.
• Willingness to provide blood sample at the time points
• Patient has or will have standard-of-care tissue genotyping ordered.

More specific eligibility requirements need to be met.

Protocol: Pancreas -S1505

A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
All patients will be randomized into two study groups, then both groups will receive chemotherapy treatment before and after surgery.
Patients must have measurable disease in the pancreas as defined in Section 10.1. CT scans or MRIs used to assess measurable disease must have been completed within 28 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form.
Patients must have resectable primary tumor based on contrast-enhanced CT or MRI of the chest, abdomen, and pelvis, where resectable is defined as:
1. No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery).
2. No involvement, or < 180° interface between tumor and vessel wall, of the portal vein and/or superior mesenteric vein; and patent portal vein/splenic vein confluence.
3. No evidence of metastatic disease.
Patients must have surgical consult to verify patient is a surgical candidate within 21 days prior to registration.
Patients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer.
Patients must be > 18 and < 75 years old.

More eligibility criteria need to be met.